Investors - Media Releases

Stay Informed

2010 2009 2008 2007 2006 2005 2004 2003

Back to list

July 23, 2010

mondoBIOTECH holding AG (SIX:RARE): Board of Directors sets the global terms of a planned capital increase

Stans, 23 July 2010 - mondoBIOTECH holding AG announces today the global terms of a share capital increase structured as a rights offering to existing shareholders (the "Rights Offering"), with shares not taken up in the Rights Offering to be placed privately by the Company with selected investors (the "Selected Offering", and together with the Rights Offering, the "Offering"). The Company's share capital will be increased out of authorized share capital by issuance of up to 100’273 fully paid-in registered common shares with a par value of CHF 0.10 each. The offer price for the newly created shares will be determined by the Board of Directors on or about 30 July 2010, after close of trading, based on the then prevailing market conditions. Under the terms of the Offering, existing shareholders will be allotted 10 subscription rights for each listed common share and 1 subscription right for each non-listed voting right share held after close of trading on the SIX Swiss Exchange on or about 30 July 2010. 660 subscription rights entitle to subscribe for one new common share at the offer price. Accordingly, 66 existing common shares and 660 voting right shares, respectively, entitle to one new common share. The subscription period for existing shareholders is expected to run from 2 August 2010 until 9 August 2010, 12.00 noon (CEST). Ex-rights trading in the existing common shares is expected to begin on 2 August 2010. The subscription rights will not be tradable on the SIX Swiss Exchange. Subscription rights not duly exercised will expire without compensation. Shares not taken up in the Rights Offering will be offered by the Company in the Selected Offering. The Company anticipates that at least approximately 65% of the offered shares will be available for the Selected Offering. The expected net proceeds from the Offering will be used to finance the further development of the Company’s product pipeline and therefore contribute to speed-up the process of making further medicinal product candidates available on the market. The first trading day of the newly issued common shares on the SIX Swiss Exchange is expected to be 13 August 2010 (ticker symbol: RARE). The new common shares will be fully fungible with the existing common shares. The offered shares will not be underwritten. Accordingly, the exact number of common shares to be issued depends on the total amount of subscriptions received in the Offering. About Mondobiotech mondoBIOTECH holding AG (SIX Swiss Exchange ticker symbol: RARE), an independent, internet-based biotech research company, discovers drugs for patients suffering from rare and neglected diseases. Mondobiotech has built a continuously growing global community of biologists, biochemists, physicians, patients and patient advocacy organizations who share their passion and skills with Mondobiotech. Together with Mondobiotech, this community is searching for treatments for rare and neglected diseases. For further information please contact: mondoBIOTECH holding AG Paolo Bassanini Investor Relations Das Kloster Mürgstrasse 18 CH-6370 Stans Tel.: +41 (0) 840 200 010 Fax: +41 (0) 840 200 011 investor@mondobiotech.com www.mondobiotech.com Disclaimer The foregoing release may contain forward-looking statements. The words “anticipates”, “believes”, “estimates”, “expects”, “intends”, “may”, “plans”, “projects”, “will”, “would” and similar expressions are intended to identify forward-looking statements, although not all forward-looking statements contain these identifying words. mondoBIOTECH holding AG may not achieve the plans, intentions or expectations disclosed in its forward-looking statements and prospective investors should not place reliance on mondoBIOTECH holding AG’s forward looking statements. There can be no assurance that results of the activities and results of operations will not differ materially from the expectations. Forward-looking statements are subject to inherent risks and uncertainties, some of which cannot be predicted or quantified. Future events and actual results could differ materially from those set forth in, contemplated by or underlying the forward looking statements. mondoBIOTECH holding AG is providing the information in this press release as of this date and does not undertake any obligation to update any forward-looking statements contained in this press release as a result of new information, future events or otherwise.? THIS DOCUMENT DOES NOT CONSTITUTE AN OFFER OR INVITATION TO SUBSCRIBE FOR OR PURCHASE ANY SECURITIES. IT IS NOT BEING ISSUED IN COUNTRIES WHERE THE PUBLIC DISSEMINATION OF THE INFORMATION CONTAINED HEREIN MAY BE RESTRICTED OR PROHIBITED BY LAW. IN PARTICULAR, THIS PRESS RELEASE IS NOT BEING ISSUED IN THE UNITED STATES OF AMERICA AND SHOULD NOT BE DISTRIBUTED TO U.S. PERSONS OR PUBLICATIONS WITH A GENERAL CIRCULATION IN THE UNITED STATES. ANY NON-COMPLIANCE WITH SUCH RESTRICTIONS MAY RESULT IN AN INFRINGEMENT OF U.S. SECURITIES LAWS. SECURITIES OF mondoBiotech holding AG ARE NOT BEING PUBLICLY OFFERED OUTSIDE OF SWITZERLAND. IN PARTICULAR, THE SECURITIES OF mondoBiotech holding AG HAVE NOT BEEN REGISTERED UNDER THE U.S. SECURITIES LAWS AND MAY NOT BE OFFERED, SOLD OR DELIVERED WITHIN THE UNITED STATES OR TO U.S. PERSONS ABSENT THE REGISTRATION UNDER OR AN APPLICABLE EXEMPTION FROM THE REGISTRATION REQUIREMENTS OF THE U.S. SECURITIES LAWS. THIS DOCUMENT DOES NOT CONSTITUTE A PROSPECTUS ACCORDING TO ART. 652A OR ART. 1156 OF THE SWISS CODE OF OBLIGATIONS OR ART. 27 ET SEQ. OF THE LISTING RULES OF SIX SWISS EXCHANGE. This document is only directed at (i) persons who are outside the United Kingdom or (ii) to investment professionals falling within Article 19(5) of the Financial Services and Markets Act 2000 (Financial Promotion) Order 2005 (the “Order”) or (iii) high net worth entities, and other persons to whom it may lawfully be communicated, falling within Article 49(2)(a) to (d) of the Order (all such persons together being referred to as “Relevant Persons”). The shares are only available to, and any invitation, offer or agreement to subscribe, purchase or otherwise acquire such securities will be engaged in only with Relevant Persons. Any person who is not a Relevant Person should not act or rely on this information or any of its contents. The investment decision of any shareholder or investor should only be based on the offering circular to be prepared by the Company in connection with the Offering. The offering circular (in English language only) is expected to be available from 2 August 2010 on the Company's website (www.mondobiotech.com) and at mondoBIOTECH holding AG, Mürgstrasse 18, CH - 6370 Stans (tel.: +41 (0) 840 200 010, fax: +41 (0) 840 200 011, email: investor@mondobiotech.com). Personal Information This email is from mondoBIOTECH holding AG. The email and any files transmitted with it are intended solely for the use of the individual or entity to which they are addressed. Any unauthorized dissemination or copying of this email or its attachments, is strictly prohibited and may be illegal. If you have received the email in error please delete it from your system. Download the Newsletter in pdf format

Back to list